المؤلفون: Deiana C; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Agostini M; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Brandi G; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy., Giovannetti E; Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center (VUmc), Amsterdam, The Netherlands.; Cancer Pharmacology Lab, Associazione Italiana per la Ricerca sul Cancro (AIRC) Start-Up Unit, Fondazione Pisana per la Scienza, Pisa, San Giuliano, Italy.

المصدر: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Jul; Vol. 24 (7), pp. 525-565. Date of Electronic Publication: 2024 May 23.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Pancreatic Ductal*/drug therapy , Carcinoma, Pancreatic Ductal*/pathology , Carcinoma, Pancreatic Ductal*/therapy , Pancreatic Neoplasms*/drug therapy , Pancreatic Neoplasms*/pathology , Pancreatic Neoplasms*/therapy , Molecular Targeted Therapy* , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/administration & dosage, Humans ; Survival Rate ; Drug Resistance, Neoplasm ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Animals ; Drug Development

المؤلفون: Kato K; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. kenkato@ncc.go.jp., Kojima T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan., Hara H; Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan., Tsuji A; Department of Medical Oncology, Kagawa University Hospital, Miki, Kagawa, Japan., Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan., Satoh T; Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, Osaka, Japan., Ogata T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan., Ishihara R; Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan., Goto M; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan., Baba H; Department of Gastroenterological Surgery, Kumamoto University Hospital, Kumamoto, Japan., Nishina T; Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan., Han S; Department of Medical Oncology, MSD K.K., Tokyo, Japan., Iwakami K; Department of Medical Oncology, MSD K.K., Tokyo, Japan., Yatsuzuka N; Department of Medical Oncology, MSD K.K., Tokyo, Japan., Doi T; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan.

المصدر: Esophagus : official journal of the Japan Esophageal Society [Esophagus] 2024 Jul; Vol. 21 (3), pp. 306-318. Date of Electronic Publication: 2024 Apr 12.

نوع المنشور: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

بيانات الدورية: Publisher: Springer Country of Publication: Japan NLM ID: 101206627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1612-9067 (Electronic) Linking ISSN: 16129059 NLM ISO Abbreviation: Esophagus Subsets: MEDLINE

مواضيع طبية MeSH: Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/pathology , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Cisplatin*/administration & dosage , Cisplatin*/therapeutic use , Fluorouracil*/administration & dosage , Fluorouracil*/therapeutic use, Humans ; Male ; Female ; Middle Aged ; Aged ; Follow-Up Studies ; Japan/epidemiology ; Progression-Free Survival ; Adult ; Treatment Outcome ; Double-Blind Method ; Neoplasm Metastasis ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; East Asian People

المؤلفون: Slamon D; David Geffen School of Medicine at UCLA, Los Angeles, CA dslamon@mednet.ucla.edu., Yardley DA; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN., Hortobagyi G; University of Texas M.D. Anderson Cancer Center, Houston, TX.

المصدر: The New England journal of medicine [N Engl J Med] 2024 Jun 20; Vol. 390 (23), pp. 2221-2222.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Purines*/administration & dosage , Purines*/therapeutic use , Aminopyridines*/administration & dosage , Aminopyridines*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/therapeutic use

المؤلفون: Bellmunt J; Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Hospital del Mar Research Institute Lab (IMIM), Barcelona, Spain. Electronic address: joaquim_bellmunt@dfci.harvard.edu., Nadal R; National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

المصدر: Med (New York, N.Y.) [Med] 2024 Jun 14; Vol. 5 (6), pp. 490-492.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101769215 Publication Model: Print Cited Medium: Internet ISSN: 2666-6340 (Electronic) Linking ISSN: 26666340 NLM ISO Abbreviation: Med Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/administration & dosage , Antibodies, Monoclonal, Humanized*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/pathology , Antibodies, Monoclonal*/therapeutic use , Antibodies, Monoclonal*/administration & dosage , Antibodies, Monoclonal*/adverse effects , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology, Humans ; Urologic Neoplasms/drug therapy ; Urologic Neoplasms/pathology ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects

المؤلفون: Jabbour E; The University of Texas MD Anderson Cancer Center, Houston., Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston., Aldoss I; City of Hope National Medical Center, Duarte, California., Montesinos P; Hospital Universitari i Politècnic La Fe, Valencia, Spain., Leonard JT; Oregon Health and Science University, Portland., Gómez-Almaguer D; Hospital Universitario Dr José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico., Baer MR; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore., Gambacorti-Passerini C; University of Milano-Bicocca, Monza, Italy., McCloskey J; Hackensack University Medical Center, Hackensack, New Jersey., Minami Y; National Cancer Center Hospital East, Kashiwa, Japan., Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia L. e A. Seràgnoli, Bologna, Italy., Rocha V; Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil., Rousselot P; Centre Hospitalier de Versailles, UMR1184, Université de Versailles Paris Saclay, Paris, France., Vachhani P; University of Alabama at Birmingham., Wang ES; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Wang B; Takeda Development Center Americas Inc, Lexington, Massachusetts., Hennessy M; Takeda Development Center Americas Inc, Lexington, Massachusetts., Vorog A; Takeda Development Center Americas Inc, Lexington, Massachusetts., Patel N; Takeda Development Center Americas Inc, Lexington, Massachusetts., Yeh T; Takeda Development Center Americas Inc, Lexington, Massachusetts., Ribera JM; ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukaemia Research Institute, Badalona, Spain.

المصدر: JAMA [JAMA] 2024 Jun 04; Vol. 331 (21), pp. 1814-1823.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Medical Association Country of Publication: United States NLM ID: 7501160 Publication Model: Print Cited Medium: Internet ISSN: 1538-3598 (Electronic) Linking ISSN: 00987484 NLM ISO Abbreviation: JAMA Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/adverse effects , Imatinib Mesylate*/therapeutic use , Imatinib Mesylate*/adverse effects , Imidazoles*/therapeutic use , Imidazoles*/adverse effects , Imidazoles*/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics , Pyridazines*/therapeutic use , Pyridazines*/adverse effects, Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Young Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Fusion Proteins, bcr-abl/genetics ; Philadelphia Chromosome ; Progression-Free Survival ; Protein Kinase Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Remission Induction ; Adolescent

المؤلفون: Duan M; Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA., Leng S; Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA. Electronic address: SLeng@salud.unm.edu., Mao P; Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM 87131, USA. Electronic address: PMao@salud.unm.edu.

المصدر: Pharmacology & therapeutics [Pharmacol Ther] 2024 Jun; Vol. 258, pp. 108642. Date of Electronic Publication: 2024 Apr 16.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7905840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-016X (Electronic) Linking ISSN: 01637258 NLM ISO Abbreviation: Pharmacol Ther Subsets: MEDLINE

مواضيع طبية MeSH: Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use , Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology , Neoplasms*/drug therapy , Neoplasms*/immunology , Cisplatin*/therapeutic use , Cisplatin*/pharmacology , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/pharmacology , Immunotherapy*/methods, Humans ; Animals ; Drug Resistance, Neoplasm ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/pharmacology

المؤلفون: Nagata Y; Department of Clinical Pharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan., Toyokawa G; Department of Surgery, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan., Sugiyama A; Department of Allergology, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan., Shimamatsu S; Department of Surgery, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan., Saitoh O; Department of Clinical Pharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan., Okubo H; Department of Clinical Pharmacy, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan., Ueda H; Department of Surgery, National Hospital Organization Fukuoka National Hospital, Fukuoka, Japan.

المصدر: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Jun; Vol. 30 (4), pp. 772-776. Date of Electronic Publication: 2024 Feb 25.

نوع المنشور: Case Reports; Journal Article

بيانات الدورية: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE

مواضيع طبية MeSH: Carboplatin*/adverse effects , Carboplatin*/therapeutic use , Carboplatin*/administration & dosage , Lung Neoplasms*/drug therapy , Cisplatin*/adverse effects , Cisplatin*/therapeutic use , Cisplatin*/administration & dosage , Carcinoma, Non-Small-Cell Lung*/drug therapy , Drug Hypersensitivity* , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Male ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Paclitaxel/adverse effects ; Paclitaxel/therapeutic use ; Paclitaxel/administration & dosage ; Drug Substitution

المؤلفون: Wages NA; Department of Biostatistics, School of Population Health, Virginia Commonwealth University, Richmond, VA, USA., Dillon PM; Division of Hematology & Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA., Portell CA; Division of Hematology & Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA., Slingluff CL Jr; Division of Surgical Oncology, Department of Surgery, University of Virginia, Charlottesville, VA, USA., Petroni GR; Division of Translational Research & Applied Statistics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.

المصدر: Clinical trials (London, England) [Clin Trials] 2024 Jun; Vol. 21 (3), pp. 331-339. Date of Electronic Publication: 2024 Mar 30.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: SAGE Publications Country of Publication: England NLM ID: 101197451 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-7753 (Electronic) Linking ISSN: 17407745 NLM ISO Abbreviation: Clin Trials Subsets: MEDLINE

مواضيع طبية MeSH: Research Design* , Neoplasms*/drug therapy , Maximum Tolerated Dose* , Antineoplastic Combined Chemotherapy Protocols*/administration & dosage , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use, Humans ; Drug Development/methods ; Dose-Response Relationship, Drug ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Clinical Trials as Topic/methods

المؤلفون: Rangwala HS; Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan. srangwala01@gmail.com., Fatima H; Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan., Ali M; Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan., Sunder S; Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan., Devi S; Department of Medicine, Ghulam Muhammad Mahar Medical College, Karachi, Pakistan., Rangwala BS; Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan., Abbas SR; Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.

المصدر: Journal of the Egyptian National Cancer Institute [J Egypt Natl Canc Inst] 2024 May 06; Vol. 36 (1), pp. 14. Date of Electronic Publication: 2024 May 06.

نوع المنشور: Comparative Study; Evaluation Study; Journal Article; Meta-Analysis; Systematic Review

بيانات الدورية: Publisher: SpringerOpen Country of Publication: England NLM ID: 9424566 Publication Model: Electronic Cited Medium: Internet ISSN: 2589-0409 (Electronic) Linking ISSN: 11100362 NLM ISO Abbreviation: J Egypt Natl Canc Inst Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects , Ipilimumab*/administration & dosage , Ipilimumab*/adverse effects , Ipilimumab*/therapeutic use , Neoplasms*/drug therapy , Neoplasms*/mortality , Neoplasms*/pathology , Nivolumab*/administration & dosage , Nivolumab*/adverse effects , Nivolumab*/therapeutic use, Humans ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/administration & dosage ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/administration & dosage ; Progression-Free Survival ; Randomized Controlled Trials as Topic ; Treatment Outcome

المؤلفون: Seol A; Department of Obstetrics and Gynecology, Korea University Medical Center, Seoul, Republic of Korea., Kim SI; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea., Yoon HY; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea., Lee M; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea; marialeemd@gmail.com.; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea., Kim HS; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea., Chung HH; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea., Park NH; Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Republic of Korea.; Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea., Song YS; Department of Obstetrics and Gynecology, Myongji Hospital, Goyang-si, Republic of Korea.

المصدر: In vivo (Athens, Greece) [In Vivo] 2024 May-Jun; Vol. 38 (3), pp. 1338-1350.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8806809 Publication Model: Print Cited Medium: Internet ISSN: 1791-7549 (Electronic) Linking ISSN: 0258851X NLM ISO Abbreviation: In Vivo Subsets: MEDLINE

مواضيع طبية MeSH: Bevacizumab*/therapeutic use , Bevacizumab*/administration & dosage , Bevacizumab*/adverse effects , Drug Resistance, Neoplasm* , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/mortality , Ovarian Neoplasms*/pathology , Neoplasm Recurrence, Local*/drug therapy , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Middle Aged ; Aged ; Adult ; Treatment Outcome ; Prognosis ; Retrospective Studies ; Carcinoma, Ovarian Epithelial/drug therapy ; Carcinoma, Ovarian Epithelial/mortality ; Platinum/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/administration & dosage